ERBB2 and breast carcinoma: Triple-negative breast cancer (TNBC) is an aggressive immunogenic [1], subtype of breast cancer characterized by the absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER-2) [2], presenting significant challenges in prognostication and treatment due to limited targeted therapies.